• Recognized healthcare and life science leaders across the industry will bring breadth of insights to inform ADVI Health’s growth and customer engagement strategies
• Underscore’s ADVI’s commitment to supporting healthcare and life sciences leaders in solving complicated problems in healthcare with data informed policy, commercialization, and market access solutions

ADVI Health today announced the appointment of Sandy Royden, a distinguished healthcare and life science leader, to its Board of Directors. Royden is a highly experienced entrepreneur in the pharma services space, with 12 years spent within biopharmaceutical companies and over 20 years in the pharmaceutical services and commercialization agency environment.

From 2011 to 2022, Royden served as co-founder and Global COO of Open Health, a medical communications and market access consultancy. There, she delivered innovative, multi-channel campaigns across UK domestic, European, and US markets, organized around medical communications, value informatics, and evidence, patient, and brand solutions.

“I’m honored to welcome Sandy Royden to ADVI’s board,” said Marc Samuels, ADVI Health CEO. “She is an exceptional life sciences leader who has led some of the most well-known pharma services commercialization businesses in the world. Sandy understands how to leverage all solutions across value and access strategic consulting to ensure client success.”

Prior to co-founding Open Health, Royden was the European CEO of Huntsworth Health, now an Inizio Company. At Huntsworth Health, she led a dedicated European team of experts across advisory, medical, marketing, communications, and patient and stakeholder engagement solutions. Their focus was on the drug lifecycle, from initial assessment to loss of exclusivity. Royden has also served as Head of Healthcare Communications at Novartis and Head of the Sanofi Foundation, among other roles.

“I am thrilled to work with Marc and the team at ADVI Health and look forward to helping them advance on the successes and endeavors they’ve already made since partnering with Sheridan Capital Partners (SCP) in 2022,” said Royden. “I am eager to support the team’s efforts in developing and delivering their strategic growth plans, organic growth opportunities, and focused investments in key areas.”

ADVI Health’s Board of Directors is comprised of exceptional leaders who have demonstrated a unique understanding of the intricacies of the global pharmaceutical services and commercialization sectors. The board, which includes Scott Howell (former Chief Strategy Officer and Head of Market Access at Novartis; Head, Market Access, Jazz Pharmaceuticals; SVP, Biopharmaceutical Services at Cardinal Health), provides mission-critical insights to fuel the company’s competitive edge.